bluebird bio Inc. (BLUE)
bluebird bio Statistics
Share Statistics
bluebird bio has 9.79M shares outstanding. The number of shares has increased by 1.08% in one year.
| Shares Outstanding | 9.79M |
| Shares Change (YoY) | 1.08% |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | 1.46% |
| Shares Floating | 9.68M |
| Failed to Deliver (FTD) Shares | 12.06K |
| FTD / Avg. Volume | 2.82% |
Short Selling Information
The latest short interest is 1.99M, so 20.37% of the outstanding shares have been sold short.
| Short Interest | 1.99M |
| Short % of Shares Out | 20.37% |
| Short % of Float | 20.59% |
| Short Ratio (days to cover) | 2.07 |
Valuation Ratios
The PE ratio is -0.34 and the forward PE ratio is -1.72. bluebird bio's PEG ratio is 0.
| PE Ratio | -0.34 |
| Forward PE | -1.72 |
| PS Ratio | 0.96 |
| Forward PS | 0.1 |
| PB Ratio | -2.56 |
| P/FCF Ratio | -0.31 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for bluebird bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48, with a Debt / Equity ratio of -8.99.
| Current Ratio | 0.48 |
| Quick Ratio | 0.28 |
| Debt / Equity | -8.99 |
| Debt / EBITDA | -1.81 |
| Debt / FCF | -1.08 |
| Interest Coverage | -11.98 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $337.93K |
| Profits Per Employee | $-970.63K |
| Employee Count | 248 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | 70K |
| Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by -77.39% in the last 52 weeks. The beta is 0.47, so bluebird bio's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -77.39% |
| 50-Day Moving Average | 4.89 |
| 200-Day Moving Average | 10.36 |
| Relative Strength Index (RSI) | 51.45 |
| Average Volume (20 Days) | 427.71K |
Income Statement
In the last 12 months, bluebird bio had revenue of 83.81M and earned -240.72M in profits. Earnings per share was -24.84.
| Revenue | 83.81M |
| Gross Profit | -5.57M |
| Operating Income | -270.46M |
| Net Income | -240.72M |
| EBITDA | -156.82M |
| EBIT | -218.07M |
| Earnings Per Share (EPS) | -24.84 |
Balance Sheet
The company has 62.3M in cash and 283.36M in debt, giving a net cash position of -221.06M.
| Cash & Cash Equivalents | 62.3M |
| Total Debt | 283.36M |
| Net Cash | -221.06M |
| Retained Earnings | -4.5B |
| Total Assets | 460.23M |
| Working Capital | -166.79M |
Cash Flow
In the last 12 months, operating cash flow was -260.02M and capital expenditures -2.6M, giving a free cash flow of -262.62M.
| Operating Cash Flow | -260.02M |
| Capital Expenditures | -2.6M |
| Free Cash Flow | -262.62M |
| FCF Per Share | -27.1 |
Margins
Gross margin is -6.65%, with operating and profit margins of -322.72% and -287.23%.
| Gross Margin | -6.65% |
| Operating Margin | -322.72% |
| Pretax Margin | -287.14% |
| Profit Margin | -287.23% |
| EBITDA Margin | -187.12% |
| EBIT Margin | -322.72% |
| FCF Margin | -313.36% |
Dividends & Yields
BLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BLUE is $10, which is 123.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $10 |
| Price Target Difference | 123.2% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Dec 13, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Dec 13, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -15.46 |
| Piotroski F-Score | 3 |